ABL1 E255V

CI-VAR-00000704Explore in graph →NP_005148.2:p.Glu255ValNM_005157.5:c.764A>TClinVar 376091 CIViC 4606 rs121913449

Curated evidence

Evidence by cancer (20 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–20 of 20 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive20
BCR::ABL1 Fusion AND ABL1 E255V	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4441 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 E255V	Axitinib	Predictive	D	Supports Resistance	2	accepted	EID4442 In an in vitro study, a pro-B Ba/F3 cell line expressing E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1015nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376091	Pathogenic	no assertion criteria provided	0	Lip and oral cavity carcinoma	somatic	1	Apr 30, 2019	clinvar